BioNTech Finalizes $1.25 Billion Acquisition of CureVac, Expanding Cancer Treatment Portfolio
In a significant move within the pharmaceuticals industry, German vaccine manufacturer BioNTech has completed the acquisition of its domestic rival CureVac. The all-stock takeover, valued at approximately $1.25 billion, marks a continuation of BioNTech’s strategic expansion into cancer treatment, following its recent $11 billion partnership with US-based Bristol Myers Squibb. Legal advice for this transaction…